Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules.
The aim of this study was to investigate the possibility of developing different levels of correlation between in vitro release and in vivo absorption rate for four modified-release levosimendan capsule formulations. Differences and similarities in the in vitro dissolution curves were compared with pharmacokinetic parameters describing absorption rate. Formulations F, G, H and I differed in the amounts of the delaying excipients alginic acid and HPMC. In vitro release rate was studied by the USP basket method using the following conditions: pH 5.8 or 7.4 and a rotation speed of 50 or 100 rpm. In vivo bioavailability was tested in nine healthy male volunteers and the fractions absorbed were calculated by the Wagner-Nelson method. Dissolution conditions pH 5.8 and a rotation speed of 100 rpm predicted best the similarities and differences in absorption rates among different formulations, and levels C and B correlation coefficients were 0.85 and 0.97, respectively. For formulation H level A correlation (r=0.997) was found when in vitro lag time was 0.2 h and time scale factor 1.9. This study indicated that dissolution tests developed can be used as a surrogate for human bioequivalence studies, for development processes of final commercial products, to ensure batch to batch bioequivalence and in the future in possible scale-up and post approval change cases for modified-release levosimendan formulation H.
Kortejärvi
H
H
Orion Pharma, PO Box 65, FIN-02101, Espoo, Finland. hanna.kortejavi@orionpharma.com
Mikkola
J
J
Bäckman
M
M
Antila
S
S
Marvola
M
M
D000328:Adult; D000465:Algorithms; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D001682:Biological Availability; D002214:Capsules; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D005079:Excipients; D005260:Female; D005780:Gelatin; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D006863:Hydrogen-Ion Concentration; D008297:Male; D008954:Models, Biological; D011724:Pyridazines / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D000077464:Simendan; D012995:Solubility; D013056:Spectrophotometry, Ultraviolet; D013810:Therapeutic Equivalency
D000889:Anti-Arrhythmia Agents; D002214:Capsules; D003692:Delayed-Action Preparations; D005079:Excipients; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan; D005780:Gelatin